Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanislas Pol

Showing results (401-410 of 441) with videos related to

Pageof 45
Sort By:
JAMA|May 6, 2015
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infectionFred Poordad, William Sievert, Lindsay Mollison, et al.
JHEP Reports : Innovation in Hepatology|November 9, 2020
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence areaGiuliana Amaddeo, Raffaele Brustia, Manon Allaire, et al.
The Lancet. Infectious Diseases|March 17, 2015
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)Marc Bourlière, Jean-Pierre Bronowicki, Victor de Ledinghen, et al.
Journal of Hepatology|October 27, 2016
Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradicationAdriaan J van der Meer, Jordan J Feld, Harald Hofer, et al.
Annals of Hepatology|July 19, 2023
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What's new 12 months later?Raffaele Brustia, Mohamed Bouattour, Manon Allaire, et al.
BMC Infectious Diseases|April 4, 2019
Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohortAnne Laurain, Sophie Metivier, Georges Haour, et al.
Hepatology (Baltimore, Md.)|April 4, 2017
Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: An individual patient data-based meta-analysisEva Herrmann, Victor de Lédinghen, Christophe Cassinotto, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 10, 2011
A systematic review of hepatitis C virus epidemiology in Europe, Canada and IsraelMarkus Cornberg, Homie A Razavi, Alfredo Alberti, et al.
Oncotarget|October 4, 2017
<i>BRIP1</i> coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver diseaseAbderrahim Oussalah, Patrice Hodonou Avogbe, Erwan Guyot, et al.
Journal of Hepatology|September 14, 2016
Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patientsStanislas Pol, Marc Bourliere, Sandy Lucier, et al.
Pageof 45

Showing results (401-410 of 441) with videos related to

Sort By:
Pageof 45
JAMA|May 6, 2015
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infectionFred Poordad, William Sievert, Lindsay Mollison, et al.
JHEP Reports : Innovation in Hepatology|November 9, 2020
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence areaGiuliana Amaddeo, Raffaele Brustia, Manon Allaire, et al.
The Lancet. Infectious Diseases|March 17, 2015
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)Marc Bourlière, Jean-Pierre Bronowicki, Victor de Ledinghen, et al.
Journal of Hepatology|October 27, 2016
Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradicationAdriaan J van der Meer, Jordan J Feld, Harald Hofer, et al.
Annals of Hepatology|July 19, 2023
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What's new 12 months later?Raffaele Brustia, Mohamed Bouattour, Manon Allaire, et al.
BMC Infectious Diseases|April 4, 2019
Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohortAnne Laurain, Sophie Metivier, Georges Haour, et al.
Hepatology (Baltimore, Md.)|April 4, 2017
Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: An individual patient data-based meta-analysisEva Herrmann, Victor de Lédinghen, Christophe Cassinotto, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 10, 2011
A systematic review of hepatitis C virus epidemiology in Europe, Canada and IsraelMarkus Cornberg, Homie A Razavi, Alfredo Alberti, et al.
Oncotarget|October 4, 2017
<i>BRIP1</i> coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver diseaseAbderrahim Oussalah, Patrice Hodonou Avogbe, Erwan Guyot, et al.
Journal of Hepatology|September 14, 2016
Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patientsStanislas Pol, Marc Bourliere, Sandy Lucier, et al.
Pageof 45